ADC Series (III): ADC Linker Design and Conjugation Strategy - Why Engineering Details Define ADC Success
- Jason Lu
- Feb 7
- 4 min read
Updated: Feb 14
Introduction
This is the third article in LuTra Studio’s ADC series, written for readers without a chemistry or ADC engineering background who want to understand why many antibody–drug conjugate programs fail despite having strong targets and potent payloads.
This article focuses on ADC linker design and conjugation strategy—two elements often treated as technical details, but which frequently become structural failure points in clinical development and manufacturing scale-up.
Executive Summary
If you remember only one thing:
Most ADC failures are not caused by antibodies or payloads, but by linker and conjugation decisions made early in development.
Linkers and conjugation strategies determine:
when a payload is released
where it is released
how consistently ADC molecules behave in vivo
1. Why the ADC Linker Is the Most Underrated Component
In many introductions, the linker is described simply as:
“The chemical bridge connecting the antibody and the drug.”
In reality, ADC linker design solves a far more difficult engineering problem:
How can an ADC remain stable in circulation for days, yet reliably release its payload inside cancer cells?
To succeed, an ADC linker must simultaneously satisfy:
systemic stability
predictable intracellular release
compatibility with both antibody and payload
Any imbalance can result in correct design on paper, but incorrect behavior in vivo.
2. Cleavable vs. Non-cleavable Linkers: A System Choice, Not a Preference
Cleavable linkers
Common mechanisms include:
pH-sensitive cleavage
protease-triggered cleavage (e.g., cathepsins)
reduction-sensitive disulfide linkers
Advantages
efficient payload release
potential bystander effect
Risks
premature cleavage in circulation
strong dependence on tumor microenvironment
Non-cleavable linkers
These linkers remain intact until the antibody is degraded in lysosomes.
Advantages
high systemic stability
more predictable pharmacokinetics
Limitations
payload must remain active in a residual form
limited bystander killing
👉 The key question is not which linker is “better,” but which is system-compatible with target biology, internalization kinetics, and payload chemistry.
3. How Linkers Quietly Determine Post-Internalization Outcomes
Internalization brings ADCs into the cell—but linkers determine what happens next.
For example:
a protease-cleavable linker may fail if trafficking stalls in early endosomes
an overly stable linker may delay payload release beyond therapeutic relevance
In many failed programs, internalization was successful, but payload release timing was mismatched.
4. ADC Conjugation Strategy: Why Average DAR Is Not Enough
The hidden cost of random conjugation
Early ADCs relied on lysine- or cysteine-based random conjugation, resulting in:
wide DAR distributions
molecular heterogeneity
batch-to-batch variability
Even if the average DAR looks acceptable, real systems often show:
a small fraction of highly toxic molecules and a large fraction of minimally effective ones.
Site-specific conjugation: The engineering inflection point
Modern ADCs increasingly adopt:
engineered cysteine sites
enzyme-directed conjugation
precision chemical handles
The goal is simple:
Make every ADC molecule behave as similarly as possible.
This consistency underpins:
scalable manufacturing
regulatory robustness
platform-level reuse
5. DAR Is Not a Target — It Is an Outcome
Drug-to-antibody ratio (DAR) is often treated as a KPI, but in reality it reflects:
linker design × payload properties × conjugation strategy
High DAR does not guarantee efficacy.
Low DAR does not ensure safety.
What matters is:
DAR distribution
molecular predictability
alignment with PK and toxicity profiles
6. Why Linker and Conjugation Choices Define Platforms vs. Products
If your ADC requires:
a unique linker per payload
reinvention of conjugation chemistry per target
fragile manufacturing processes
You are building a single product.
True ADC platforms, by contrast, are designed from the outset for:
modular payload swapping
scalable conjugation
reproducible quality
From Engineering Details to Strategic Decisions | LuTra Studio Consulting
Linker and conjugation problems rarely appear early. They surface:
near IND submission
during scale-up
when toxicity becomes difficult to explain
LuTra Studio works with teams before these points, helping integrate:
internalization behavior
linker chemistry
conjugation strategy
platform scalability
If you want to reduce late-stage surprises caused by early engineering assumptions, we welcome the conversation.
What’s Next | ADC Series (IV)
Next, we will step even further upstream:
Target and Antigen Selection: Which Biological Conditions Truly Suit ADCs?
References
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N.
Antibody–Drug Conjugates: Present and Future.
Nature Reviews Drug Discovery, 2017.
Lambert, J. M., & Morris, C. Q.
Antibody–Drug Conjugates (ADCs) for Targeted Cancer Therapy.
Advanced Therapy (Adv Ther), 2017.
Jain, N., Smith, S. W., Ghone, S., & Tomczuk, B.
Current ADC Linker Chemistry.
Pharmaceutical Research, 2015.
Ducry, L., & Stump, B.
Antibody–Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies.
Bioconjugate Chemistry, 2010.
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R.
Site-Specific Antibody–Drug Conjugates for Cancer Therapy.
mAbs, 2014.
Casi, G., & Neri, D.
Antibody–Drug Conjugates: Basic Concepts, Examples and Future Perspectives.
Journal of Controlled Release, 2012.
https://www.sciencedirect.com/science/article/pii/S0168365912002969
Shen, B. Q., et al.
Conjugation Site Modulates the In Vivo Stability and Therapeutic Activity of Antibody–Drug Conjugates.
Nature Biotechnology, 2012.
Hamblett, K. J., et al.
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody–Drug Conjugate.
Clinical Cancer Research, 2004.
https://aacrjournals.org/clincancerres/article/10/20/7063/198458
Junutula, J. R., et al.
Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index.
Nature Biotechnology, 2008.
ADC Review / Journal of Antibody–Drug Conjugates.
Linker and Conjugation Strategies in Next-Generation ADCs.
Industry editorials and reviews.
Journal of Hematology & Oncology (Springer / BioMed Central).
Antibody–Drug Conjugates: Current and Future Biopharmaceuticals.
Journal of Hematology & Oncology, 2025.
https://link.springer.com/article/10.1186/s13045-025-01704-3
Comments